IGEA Research Corporation is a research company in the biomedical field with a new innovative concept, specializing in the measurement of free circulating copper in the blood. Thanks to a network of worldwide renown researchers, our goal is to give patients who are at risk of becoming affected with Alzheimer's disease, the opportunity to modify its main risk fac-tor in order to improve their quality of life. As very small changes in the brain begin, long before the first signs of memory loss, symptoms usually develop slowly and get worse over time, becoming severe enough to interfere with daily tasks.After 15 years and many research projects aimed at investigating the different metabolic pro-cesses that Alzheimer's disease alters, Igea Research Corporation has discovered a disturb-ance in copper metabolism, which has strong effects on the patient's cognitive state and medi-cal condition. Igea Research Corporation has developed a fast and efficient test system to measure the levels of non Cp-Copper, also known as ‘free copper', which is the number one risk factor in Alz-heimer's disease. It is now on the market under the name ALZ-1 test and thanks to our studies today it is now possible to determine, in a quantitative and reliable manner its levels.The ALZ-1 TestALZ-1 is an innovative test that can measure the quantity of Non-Cp copper concentration in serum, through a simple blood sampling. The test is accurate, sensitive and reliable to measure Non-Cp copper circulating through a fluorescent probe set up ad hoc (Ref Patent: PCT/EP2012/ 072063). If the value is not within the normal range, you have the possibility to be followed up by our physician and nutritionists for a low copper diet to restore the normal physiological levels .How to testA simple blood test at our certified laboratory or at an affiliated Center is sufficient.